CD19嵌合抗原受体修饰T细胞治疗后重度细胞因子释放综合征的动力学与生物标志物
该研究纳入133例接受CD19 CAR T细胞治疗的成人患者,70%发生细胞因子释放综合征(CRS),其中4级和5级各占3.8%。多变量分析确定高骨髓肿瘤负荷、环磷酰胺联合氟达拉滨清淋、较高CAR T细胞剂量、清淋前血小板减少及未筛选CD8+中央记忆T细胞制备为CRS独立预测因素,并发现血管生成素-2和血管性血友病因子在重度CRS期间及清淋前升高。
要点
- 133例接受CD19 CAR T细胞治疗的成人中70%发生CRS,4级和5级各占3.8%。
- 高骨髓肿瘤负荷、环磷酰胺联合氟达拉滨清淋、较高CAR T细胞剂量等为CRS独立预测因素。
- 血管生成素-2和血管性血友病因子在重度CRS期间及清淋前升高。
核心结论
- 重度CRS以血流动力学不稳定、毛细血管渗漏和消耗性凝血病为特征,血管生成素-2和血管性血友病因子在重度CRS期间及后续发生CRS患者清淋前升高。
- 研究描述了一种分类树算法,用于指导对高重度CRS风险患者进行CAR T细胞输注后早期干预研究。
研究设计与样本
- 研究纳入133例接受CD19 CAR T细胞治疗的成人患者,报告临床表现并识别重度CRS的生物标志物。
主要发现
- 70%患者发生CRS,其中1至3级占62.5%(1级26%、2级32%、3级4.5%),4级占3.8%,5级占3.8%。
- 多数4级及以上CRS发生在CAR T细胞剂量探索期间。
- 多变量分析确定高骨髓肿瘤负荷、环磷酰胺联合氟达拉滨清淋、较高CAR T细胞剂量、清淋前血小板减少及未筛选CD8+中央记忆T细胞制备为CRS独立预测因素。
- 血管生成素-2和血管性血友病因子在重度CRS期间升高,且在后续发生CRS患者的清淋前即升高。
临床怎么用
- 原文描述了分类树算法以指导对高重度CRS风险患者进行CAR T细胞输注后早期干预研究,未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphodepletion chemotherapy followed by infusion of CD19-specific chimeric antigen receptor-modified (CAR) T cells has produced impressive antitumor responses in patients with refractory CD19+ B-cell malignancies but is often associated with cytokine release syndrome (CRS). Our understanding of CRS continues to evolve, and identification of the kinetics of CRS and predictive clinical and laboratory biomarkers of severity are needed to evaluate strategies to mitigate toxicity. We report the clinical presentation of and identify biomarkers of severe CRS in 133 adult patients who received CD19 CAR T cells. CRS developed in 70% of patients, including 62.5% with grade 1 to 3 CRS (grade 1, 26%; grade 2, 32%; grade 3, 4.5%), 3.8% with grade 4, and 3.8% with grade 5. A majority of cases of grade ≥4 CRS occurred during CAR T-cell dose finding. Multivariable analysis of baseline characteristics identified high marrow tumor burden, lymphodepletion using cyclophosphamide and fludarabine, higher CAR T-cell dose, thrombocytopenia before lymphodepletion, and manufacturing of CAR T cells without selection of CD8+ central memory T cells as independent predictors of CRS. Severe CRS was characterized by hemodynamic instability, capillary leak, and consumptive coagulopathy. Angiopoietin-2 and von Willebrand factor, which are biomarkers of endothelial activation, were increased during severe CRS and also before lymphodepletion in patients who subsequently developed CRS. We describe a classification-tree algorithm to guide studies of early intervention after CAR T-cell infusion for patients at high risk of severe CRS. These data provide a framework for early intervention studies to facilitate safer application of effective CD19 CAR T-cell therapy.
引用
- Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017. PMID: 28924019. doi:10.1182/blood-2017-06-793141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。